Brief: Forte Biosciences Inc Announces First Patient Dosed In The Clinical Trial Of FB-401 For The Treatment Of Children And Adults With Atopic Dermatitis

Forte Biosciences

29/09/2020 14:54

Sept 29 (Reuters) - Forte Biosciences Inc  FBRX.O :
    * FORTE BIOSCIENCES, INC. ANNOUNCES FIRST PATIENT DOSED IN
THE
CLINICAL TRIAL OF FB-401 FOR THE TREATMENT OF CHILDREN AND
ADULTS WITH ATOPIC DERMATITIS

Source text for Eikon:  ID:nBw8Yrc9ma 
Further company coverage:  FBRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))